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Abstract
Cerebral palsy (CP) is the most common cause of physical disability in children. CP cur-
rently has no cure and there are only few interventions to prevent the development of 
disability. There are four principal complications of pregnancy or birth that can damage 
the developing brain and lead to CP: preterm birth, fetal growth restriction, infection 
during pregnancy and severe hypoxia-ischemia at birth. Umbilical cord blood (UCB) 
cells are a very promising therapy for the treatment of CP. While UCB therapy for juve-
niles with CP is currently being assessed in clinical trials, very little is known about their 
mechanisms of action or which cells found in umbilical cord blood protect against and/
or repair brain injury. In this chapter, we first explore the complications that can lead 
to perinatal brain injury. We then discuss the different cell types found in UCB and the 
specific properties that make each of them individually attractive therapeutic candidates 
for treatment of perinatal brain injury. While UCB holds much promise as a therapy for 
CP, it is imperative that more research is conducted to understand how the different cell 
types found in UCB can protect against brain injury in order to design more effective and 
targeted therapies.
Keywords: cerebral palsy, stem cells, hypoxic-ischemic injury, early intervention, 
neonatal, fetal growth restriction, Intrauterine growth restriction 
1. Introduction
Perinatal brain injury is the underlying cause of cerebral palsy (CP), which is a broad term 
used to describe deficits in motor function and/or posture. CP affects more than 1 in 450 live 
births in developed countries and the incidence of severe disability is much higher in low 
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resource countries. There are four principal complications affecting pregnancy or birth that 
can lead to perinatal brain injury: preterm birth, fetal growth restriction, infection during 
pregnancy or severe hypoxia-ischemia at birth (birth asphyxia). The time of onset of these 
complications is different for each condition and other important variables that affect the 
severity of the resulting brain injury exist. These include the severity of the insult, whether the 
infant is born preterm or at term and whether complications are compounded (for example, 
an asphyxic event at birth in a growth restricted infant). Although these complications vary 
in their fundamental etiology, they share common neuro-pathological features that include 
hypoxic episodes, inflammation, excitotoxicity and decreased vascular integrity. Umbilical 
cord blood (UCB)-derived cells demonstrate the potential to mediate these adverse pathways 
and, thereby, have neuroprotective, neuroregenerative and angiogenic potential for transla-
tion into clinical treatments for perinatal brain injury.
UCB is a proven source of hematopoietic stem cells (HSCs) used clinically for treatment of 
hematological disorders, but it also contains a number of other stem/progenitor cell types, of 
which mesenchymal stromal cells (MSCs) and endothelial progenitor cells (EPCs), individu-
ally or together, offer neuroprotective benefits [1, 2]. Moreover, UCB is also a rich source of 
immunosupressive cells, such as T regulatory cells (Tregs) and monocyte-derived suppres-
sor cells (MDSCs) [3]. There is supporting evidence that in isolation, each of these cell types 
have properties that may prevent the progression of hypoxic and inflammatory cascades that 
drive brain injury; however, their ability to prevent neonatal brain injury has not been well 
explored. It is likely that each cell type targets different pathways to reduce or repair tissue 
injury. The study of the properties of whole UCB, as well as its individual cellular compo-
nents, in animal models of perinatal brain injury is integral towards the development of tai-
lored cell therapy to prevent or repair brain injury in high risk newborn infants. Furthermore, 
the importance of the timing of administration needs to be further explored. Current clinical 
trials are administering UCB cells to children that have established CP, with children ranging 
from 10 months to 20 years old. In contrast, preclinical evidence suggests that administration 
of UCB cells at an early stage after injury, and while the brain is still plastic and receptive, 
should be much more effective than later intervention at protecting the brain and promoting 
brain repair.
2. Complications associated with perinatal brain injury
2.1. Term hypoxic-ischemic brain injury
In the healthy term-born infant, the brain continues to develop after birth. The formation of 
neurons and glial cells is mostly complete by term, however cell maturation, myelination 
and synaptic connection continue well after birth [4]. At term, the brain is very vulnerable 
to changes in the environment to which it is exposed and a hypoxic-ischemic (HI) insult at 
this time can induce an inflammatory response, as well as increased excitotoxicity, release of 
reactive oxygen species, and apoptotic cell death [5]. When term born infants are exposed to 
a severe hypoxic insult at, or around, the time of birth the resulting pattern of brain injury is 
seen as a selective disruption of cortical and deep grey matter structures, which include the 
putamen, ventrolateral thalamus and the cortex [6]. This type of severe HI injury results in the 
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clinical condition termed hypoxic ischemic encephalopathy (HIE), which manifests in infants 
as a range of clinical abnormalities that include truncal hypotonia and dystonia, jitteriness, 
severe comas and seizures [6, 7]. HIE affects approximately 1.5 in 1000 live births each year in 
developed countries [8] and is the most well understood form of perinatal brain injury with 
respect to the progression of brain damage and subsequent neurodevelopmental outcomes. 
The underlying cause of the severe HI episode is not always known, but is most often associ-
ated with umbilical cord prolapse, placental abruption, or prolonged labor, while other ante-
natal insults may also be involved [9].
The development of HIE and cell degeneration after a severe insult at birth progresses over 
time and has been described as a series of phases originating from the time of the insult 
[10]. The severity and length of these phases can be useful indicators of the severity of future 
neurological deficits in the infant [11]. The initial phase is the insult or primary phase, which 
describes the period of hypoxic insult often referred to as the phase of primary energy fail-
ure. In this phase, there is an acute severe reduction in cerebral perfusion leading to a lack of 
oxygen and glucose within the brain, with exhaustion of high-energy stores and rapid accu-
mulation of lactic acid and free radicals [12]. In turn, this induces excitotoxic programming 
of the apoptotic cascade, leading to commencement of primary cell loss [2]. Following the 
cessation of the insult and oxygen reperfusion, the latent phase begins from the onset of reper-
fusion up to approximately 6 h after injury and gives the appearance of restored metabolic 
function due to restoration of blood flow and oxygen to the brain [12]. This is associated with 
reduced oxygen consumption and restoration of normal metabolite levels [13]. However, 
this phase is short lived and is closely followed by a secondary phase of deterioration and 
brain injury.
The secondary phase is critical, because, even when the primary phase has been very severe, 
most neuronal death results from events that occur during the secondary phase [14]. During 
the secondary phase, the pro-inflammatory pathways become significantly upregulated, 
which, in turn, contributes to breakdown of the blood brain barrier (BBB). These events are 
both key contributors to brain damage. As occurs in the primary phase, elevated glutamate 
is also apparent, resulting in an excitotoxic environment, and exacerbation of cell death [12]. 
It is during the secondary phase that seizures will commence in those infants with moderate 
to severe encephalopathy [15]. The secondary phase of insult occurs between 6 h and up to 3 
days after the HI insult.
In addition to the neurotoxic events described above, in response to HI, the transcription fac-
tor hypoxia inducible factor-1α (HIF-1α) is upregulated, which, in turn, upregulates genes 
such as vascular endothelial growth factor (VEGF) [16]. Increased VEGF leads to increased 
vascular permeability, causing vascular leakage, which further contributes to the breakdown 
of the BBB. This increased permeability allows immune cells to infiltrate into the brain paren-
chyma, where they can secrete growth factors and cytokines that have the ability to activate 
nearby cells, such as microglia and astrocytes [17]. The first immune cells that are activated 
by ischemia are the resident microglia and astrocytes, which home to the ischemic area and 
begin to “clean up” the damaged area, by means of phagocytosis. During this surge of inflam-
mation, there is an increase in pro-inflammatory cytokines, specifically interleukin (IL)-6 and 
IL-8, which are produced by activated microglia, and an influx of T cells to the site of the 
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lesion. This increase in IL-6 and IL-8 is known to be associated with the development of cere-
bral palsy following a HI insult [18]. Microglia and astrocytes add to the production of reac-
tive oxygen species (ROS), causing further oxidative stress [19]. The functional role of T cells 
following their influx in response to ischemia is not fully known, however, it has been shown 
that, when T cells are suppressed, there is a reduction in inflammation at the site of the infarct. 
It has also been noted that, in response to a HI insult, there is reduced recruitment of regula-
tory T cells (Tregs) to the site of injury [20], Tregs are part of our natural anti-inflammatory 
defence system and a failure to recruit these cells may contribute to increased inflammation 
and brain injury.
In addition, during the secondary phase of brain injury, vasogenic edema begins as a result of 
the breakdown of the BBB and infiltration of blood products. Plasma and serum proteins leak 
out of the vessels and into the extracellular space of the brain. Brain edema can cause further 
injury to the brain by compressing surrounding tissues, compressing capillaries causing tis-
sue hypoxia and mediating further cell death. Using magnetic resonance imaging, it has been 
found that 86% of term neonates that have suffered a perinatal hypoxic-ischemic event also 
developed brain edemas [17].
2.2. Fetal growth restriction
Fetal growth restriction (FGR) describes the fetus that fails to grow appropriately in utero, 
most often caused by poor placental function. FGR is associated with high perinatal mortal-
ity and long-term morbidities [21]. Normal fetal growth is dependent on the efficient transfer 
of nutrients and oxygen from the maternal-uterine circulation to the fetus via the placenta. 
Inefficient placental function, and thereby inadequate oxygen, glucose and essential amino 
acid transfer to the fetus, negatively affects fetal growth [22]. Chronic hypoxia caused by 
placental insufficiency has a profound adverse effect on brain development, impacting cell 
growth and maturation, in the last third of pregnancy in particular, which in turn leads to 
brain structural alterations and functional impairments [23]. A number of follow-up stud-
ies on infants following FGR show that it is associated with significant neurodevelopmental 
disabilities, including abnormalities in fine and gross motor skills, cognitive function, lan-
guage, memory, concentration, attention, mood and school performance. FGR infants are 
also at increased risk of acute adverse neonatal consequences such as preterm birth, perinatal 
asphyxia and respiratory distress [24], which in turn exacerbate brain injury. Additionally, 
premature infants born with FGR constitute a very vulnerable population since they are at 
increased risk for an adverse neurological outcome [25].
The brain injury that is observed in human infants with FGR, and in animal models of FGR, 
is complex and distinct from other complications of pregnancy or birth. This is likely due to 
the chronic nature of hypoxia and hypoglycemia that the growth restricted fetus experiences 
over a critical period of brain development [23]. Specifically, abnormalities such as reduced 
total neuronal number, decreased axonal and synaptic density and myelin loss have been 
well described in humans and animal models of FGR [23]. Brain imaging of human FGR 
newborns also demonstrates that total brain volume, grey matter and white matter volume 
are all significantly reduced in FGR infants [26, 27]. Chronic hypoxia, caused by placental 
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 insufficiency, induces a redistribution of fetal cardiac output to favor the brain: an adaptive 
response known as brain sparing. Although the fetus is able to adapt to hypoxia, to some 
degree, this beneficial blood flow redistribution does not ensure normal brain development 
over a prolonged period. The initial increase in cerebral perfusion seen in FGR fetuses is 
followed by a pronounced fall in perfusion with progressive fetal deterioration [28]. When 
hypoxia is chronic, fetal deterioration is characterized by reduced physiological cerebral 
vascular variability (both vasoconstriction and vasodilatation), followed by an increase in 
cerebral vascular resistance, which, in turn, exacerbates brain injury [29]. Even in clinically 
healthy FGR term neonates, higher venous hematocrit and lower cerebral blood flow have 
been reported during the early neonatal period (48–72 h), with some of these infants showing 
hypertonia and delayed developmental milestones, along with hypoxic changes observed in 
magnetic resonance imaging (MRI) of the brain [30].
Neurodevelopmental abnormalities seen in FGR have been described for specific brain areas 
including the anterior hippocampal-prefrontal network, parahippocampal complex, striatum 
and thalamus [31, 32]. Magnetic resonance imaging (MRI) studies consistently demonstrate 
structural brain changes in FGR infants during both the fetal and neonatal period. These 
changes include decreased volume in cortical grey matter (GM) [26] and the hippocampus 
[33]; altered cortical development [34]; and abnormal structure of white matter tracts [35]. 
FGR infants born prematurely show a significant reduction in intra-cranial volume and cere-
bral cortical grey matter on MRI within the first 2 weeks of life, compared with age-matched 
premature non-FGR infants [26]. Similarly, FGR infants who are born preterm show a reduc-
tion in hippocampal gray matter volume, which is associated with neurobehavioral deficits at 
term equivalent and at 24 month corrected age [33].
FGR can also lead to a specific pattern of hypoxic-ischemic and/or hemorrhagic white mat-
ter lesion that can be observed on ultrasound [36]. FGR infants born prematurely show an 
increased prevalence of white matter damage on brain ultrasound scans compared to pre-
term neonates that have not been subjected to FGR, the former being associated with motor 
and cognitive impairments [35]. It has been suggested that the pathogenesis of brain injury 
in FGR involves oxidative stress that leads to periventricular white matter injury due to dam-
age to oligodendrocytes, impaired myelination and astrogliosis [37]. Neurocognitive and 
behavioral deficits seen in FGR infants have also been attributed to suboptimal gray and 
white matter connectivity. Diffusion-weighed MR imaging and tractography studies also 
show diffuse white matter injury, which may be caused by disturbances in cortico-thalamic 
connectivity [26].
In addition to connectivity alterations, significant changes have been described in brain vas-
culature of FGR neonates. The loss of cerebrovascular autoregulation that occurs in FGR is 
known to contribute to the development of intraventricular hemorrhage (IVH) and periven-
tricular leukomalacia (PVL) in neonates [38, 39]. Cerebral white matter (WM) is extremely 
vulnerable to perfusion-related injury because it receives only 25% of the blood flow of corti-
cal grey matter and, during development, is immature in its ability to autoregulate blood 
flow [40]. Under-perfusion of WM regions of the fetal brain would likely have a significant 
effect on brain development in the later stages of gestation, when myelination is at its peak 
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[41]. Fetal  cerebral vessels are one of the vascular beds most sensitive to poor substrate deliv-
ery caused by pathological conditions during intrauterine life. Despite this, research on the 
pathogenesis of perinatal brain injury in FGR has focused on excitotoxicity, oxidative stress 
and inflammatory response, with the response of the developing cerebral vasculature receiv-
ing little attention. Although IVH has been thought to occur mainly in preterm infants ≤32 
weeks of gestation, two large recent population-based studies reported that the incidence 
of IVH was low in FGR infants born <28 weeks’ gestation compared with non-FGR preterm 
infants, but there was increased frequency of IVH in FGR infants born 34–40 weeks’ gestation 
[42, 43]. These data confirm that FGR is indeed a significant risk factor for IVH in late-preterm 
and term infants.
2.3. Chorioamnionitis
Chorioamnionitis describes infection of the fetal membranes during pregnancy, typically 
results from ascending bacterial contamination from the vagina into the uterus, and is a prin-
cipal cause of preterm delivery [44]. Chorioamnionitis manifests clinically with maternal 
fever, uterine tenderness and maternal or fetal tachycardia. There is no specific treatment for 
this condition aside from antibiotics. Many cases of chorioamnionitis are, however, clinically 
silent, diagnosed by histological examination for increased infiltration of neutrophils into the 
fetal membranes after birth [45].
Chorioamnionitis can induce a fetal inflammatory response characterized by an increase in 
pro-inflammatory cytokines, including interleukin (IL)-6 and IL-1β that are detectable in the 
systemic circulation and the brain of neonates, after birth [46]. This rapid increase in cytokines 
leads to mobilization of immune effector cells into the peripheral circulation. These cells can 
then cross the blood brain barrier (BBB) and activate microglia, which leads to further release 
of pro-inflammatory cytokines and reactive oxygen species and initiates cellular excitotox-
icity [47]. Animal studies strongly support these findings and have shown that, in models 
using lipopolysaccharide administration to induce a fetal inflammatory reaction, microglia 
are activated in the white matter [48] and BBB integrity is compromised [49], allowing further 
infiltration of immune cells and large molecules into the brain. These processes of inflamma-
tion lead to damage to immature oligodendrocytes (the cells that make myelin) within the 
developing brain, resulting in hypomyelination and profound white matter injury [50]. To 
support the theory of an excessive pro-inflammatory response leading to white matter injury, 
maternal administration of anti-inflammatory IL-10 prevents inflammation and white matter 
injury in a rat chorioamnionitis model [51]. In human studies, chorioamnionitis and a subse-
quent fetal systemic inflammatory response is strongly associated with the development of 
cerebral palsy [52].
2.4. Preterm birth
Preterm birth (>37 weeks of gestation) is the most important cause of neonatal mortality and 
morbidity, with the smallest and youngest infants at greatest risk of short-term and long-term 
adverse consequences. In 2010, it was estimated that preterm births complicated 11.1% of all 
live births worldwide and preterm birth complications are the largest direct cause of neonatal 
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deaths, accounting for a million infant deaths a year [53]. Improvements in neonatal intensive 
care have greatly improved survival of preterm infants; however, these infants remain vulner-
able to many complications in the perinatal period, including respiratory distress syndrome, 
chronic lung disease, injury to the intestines, a compromised immune system, cardiovascular 
disorders, hearing and vision problems and neurological insult. Long-term neurodevelop-
mental sequelae associated with prematurity are cerebral palsy, mental retardation, learning 
difficulties and poor health and growth [54]. Advances in neuroimaging now play an impor-
tant role in the diagnosis and management of the preterm infant. Both cranial ultrasound and 
conventional MRI techniques are useful in diagnostic and prognostic evaluation of preterm 
brain development and injury. While both the grey and white matter of the brain are sus-
ceptible to altered development and injury in preterm-born infants, it is well recognized that 
white matter injury is the primary neuropathology associated with preterm birth, particularly 
those infants born extremely preterm (<28 gestation) [55].
The most common white matter neuropathologies described in preterm infants are intraven-
tricular hemorrhage (IVH) and periventricular leukomalacia (PVL), where both are strongly 
linked to adverse cognitive and motor outcomes. The pathogenesis of PVL in preterm birth 
relates to three maturation-dependent processes with the brain: (i) an incomplete state of 
development of the vascular supply to cerebral white matter; (ii) impairment in regulation 
of cerebral blood flow to cerebral white matter and (iii) vulnerability of oligodendroglial pre-
cursor cells—the major cellular target in PVL [41]. Although white matter injury is the pre-
dominant neuropathology of prematurity, this is frequently accompanied by neuronal and 
axonal injury affecting the thalamus, basal ganglia, cerebral cortex, brain stem and cerebellum 
and is termed “encephalopathy of prematurity” [55]. Additionally, two types of PVL have 
been described: cystic PVL, (cavitation and periventricular cyst formation) and non-cystic 
PVL, which is a more widespread and diffuse injury with glial scar formation. Diffuse white 
matter injury, together with gray matter and hippocampal abnormalities [56], are now the 
most common types of cerebral abnormalities associated with prematurity as focal necrotic 
lesions characteristic of cystic PVL are now rarely observed in premature infants in developed 
 countries [57].
The etiology of cerebral lesions in the preterm infant remains somewhat unclear, but it is 
generally accepted that hypoxic and inflammatory pathways are involved [58]. Preterm 
infants have a propensity to develop HI, particularly within the white matter. Intrauterine 
exposure to infection and fetal inflammation are also related to an increased risk for PVL and 
cerebral palsy. Cerebral vascular development is incomplete in prematurely born infants, 
with under-vascularized end-zones in cerebral white matter [59, 60]. Long penetrating ves-
sels, derived mainly from the middle cerebral arteries, terminate in the deep periventricular 
white matter and are the most sensitive to changes in cerebral perfusion [61]. Active develop-
ment of the periventricular vasculature occurs in the last 16 weeks of gestation [62], thus the 
increased vulnerability to ischemia in very premature infants may be related to immaturity 
of the vascular bed. Physiologically, positron emission tomography (PET) studies show that 
cerebral blood flow in the white matter of premature infants is very low (only 25% of CBF to 
the  cortex) [40], and white matter, therefore, may be vulnerable to even slight decreases in 
 cerebral perfusion [63].
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Germinal matrix hemorrhage (GMH) can be observed in preterm neonates, particularly those 
born <30 weeks’ gestation, and is more common when babies suffer additional complications 
such as respiratory distress syndrome, pneumothorax, or high blood pressure [64]. GMH 
is contributed by fragile blood vessels within the germinal matrix of the brain, particularly 
during the period of high cell proliferation (24–32 weeks’ GA) associated with corticogenesis. 
Over this period of gestation the oxygen and nutrient demand of the germinal matrix is high, 
and therefore blood flow is relatively high, however, the vessels remain immature and fragile 
[65]. GMH is associated with bleeding into the brain’s ventricles (IVH), principally because 
of their close proximity. The etiology of GMH and IVH are not well understood but may be 
linked to deficient autoregulatory capacity and pressure-passive cerebral perfusion, although 
it is unclear if hypo- or hyper-tension, or increased intravascular pressure, leads to rupture of 
cerebral vessels [66].
At the cellular level, it is now established that white matter injury in preterm infants is pre-
dominantly due to vulnerability of immature oligodendrocytes, which are in a phase of active 
development during weeks 24–40 of gestation [41, 63]. These pre-oligodendrocytes are exqui-
sitely sensitive to altered intracerebral environment and insults that may include hypoxia, 
ischemia, inflammation, excitotoxicity and free-radical attack [67]. More recently, experimen-
tal animal and human autopsy data have shown that myelination failure is primarily due to 
arrested maturation of the oligodendrocyte lineage at the pre-oligodendrocyte stage, rather 
than depletion of the oligodendrocyte pool [68]. Oligodendrocyte maturation from pre-oligo-
dendrocytes to immature and mature myelinating oligodendrocytes occurs between about 
24 and 32 weeks of human gestation, which corresponds to a critical period for preterm birth 
and white matter brain injury [69]. Long-term follow up MRI studies of preterm infants show 
a long-term reduction in brain cortical surface area, cortical folding and volume of subcortical 
and white matter regions, in addition to microstructural abnormalities and functional deficits 
[70–72]. Furthermore, it has been suggested that the neurological deficits apparent in pre-
term infants are strongly associated with decreased neuronal connectivity, with a significant 
link between frontal and temporal lobe volumes and thalamic and cortical white matter tract 
reduction [73], in preterm infants (median 28 weeks’ gestation) with further tractrography 
studies revealing reduced connectivity between the thalamus and the cortex [74]. Disruption 
of early contact between these two brain structures may also disrupt connectivity and result 
in remodeling of cortical circuitry [75].
3. Umbilical cord blood as a therapy for perinatal brain injury
A number of identified sources of stem cells have been examined for their neuroprotective 
benefits. Traditionally, stem cells derived from bone marrow have been examined for their 
use in treatment of hematological diseases and were the first stem cells trialed in most pre-
clinical neurological/neurodegenerative studies. Umbilical cord blood (UCB) is a particularly 
promising source of stem and progenitor cells that is appealing for treatment of perinatal 
brain injury—UCB is readily available at birth for routine collection, particularly in situations 
of compromised (preterm or term asphyxia) births; contains large numbers of mononuclear 
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cells with a heterogeneous population of stem and progenitor cells [76]; has low immunoge-
nicity and low risk of rejection, therefore allowing the potential for allogeneic administration 
[77]. UCB cells demonstrate high plasticity with an eightfold greater proliferation potential 
compared to other cell sources such as bone marrow [78]; and can be stored for long periods 
of time, with studies showing that, after 10+ years of cryopreservation, viable cell recovery is 
still very high [79].
Principally, the beneficial properties of UCB are dependent on the mononuclear cell compo-
sition, with this cell fraction comprising five important cell types (Figure 1)—mesenchymal 
stromal cells (MSCs), endothelial progenitor cells (EPCs), hematopoietic stem cells (HSCs), 
T regulatory cells (Tregs) and monocyte-derived suppressor cells (MDSCs) [80]. Each of these 
cell types is readily identifiable in human cord blood by their cell surface markers. In isola-
tion, each of these populations exhibits properties that could contribute to preventing the 
cascade of brain injury that transpires after perinatal hypoxia-ischemia.
3.1. Umbilical cord blood—mononuclear cells
UCB mononuclear cells are the fraction of cells that are collected after gradient separation of 
red blood cells and plasma. This fraction of cells includes lymphocytes, monocytes and all 
stem and progenitor cells. Most studies investigating the potential of UCB use this mononu-
clear fraction. Initial neuroprotection studies were performed in adult stroke models, induced 
via middle cerebral artery ligation in rats [81, 82]. Interestingly, factors released from injured 
brain tissue increased the chemo-attraction of UCB cells compared to exposure to normal 
brain tissue, indicative that UCB cells do indeed have the ability to home to sites of injury [82]. 
Another study administered mononuclear cells intravenously at 48-h post-stroke and showed 
Figure 1. Potential therapeutic cell types found in umbilical cord blood.
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white matter protection [81] and, in vitro, UCB cells were able to protect oligodendrocytes by 
reducing the expression of caspase-3 and lactate dehydrogenase.
A number of studies have since investigated the potential of UCB mononuclear cells for the 
treatment of neonatal brain injury, using a modified adaptation of the Rice-Vannucci model 
[83] for induction of hypoxic-ischemic brain injury in day 7 neonatal rat pups. Administration 
of 2 million UCB mononuclear cells at 3 h after HI reduced neuronal degeneration and cas-
pase-3 expression by 25% and, at 7 days, microglial activation was significantly reduced in 
the cortex [84]. UCB given 24-h post-neonatal HI injury normalized toe spread and forepaw 
symmetry, increased sensorimotor electrophysiology and decreased spastic paresis [84, 85]. 
Wang et al. [86] administered UCB cells directly into the ventricles, 24-h post-HI injury, and 
showed a decrease in neuronal loss in the cortex and CA1 region of the hippocampus. This 
was associated with an increase in neural stem cells within the subventricular zone and an 
increase in sonic hedgehog (Shh) and its effector Gli-1. We were the first to publish preclinical 
data evaluating the efficacy of UCB cells in large animal models of fetal and neonatal HI brain 
injury [87, 88]. Using a term birth asphyxia sheep model, we showed that UCB therapy at 
12-h post-HI insult reduced neuronal cell death, astrogliosis and inflammation [87]. We have 
recently demonstrated that UCB cells reduce white matter brain injury in preterm sheep when 
cells are administered at 12-h post-HI, and to a lesser extent when administered at 5 days after 
HI, acting to reduce neuroinflammation and protecting oligodendrocytes [88]. UCB mono-
nuclear cells are also now being used in human clinical trials for established cerebral palsy, 
but this is discussed in detail later in the chapter.
3.2. UCB-derived hematopoietic stem cells
UCB was first investigated due to its rich population of hematopoietic stem cells (HSCs). 
HSCs are positive for CD34 and characterized by their ability to self-renew, and to repopulate 
the immune system, and thus are used clinically for the treatment of many hematological 
disorders. In recent years, CD34+ cells from UCB and other sources have been investigated as 
therapies for non-hematological diseases. In an adult stroke model, transplantation of CD34+ 
cells 24-h post-stroke has been shown to significantly improve motor function, but this is 
highly dependent on administration timing as, when cells are given at 7 days, they were not 
as effective [82]. When stroke was induced in adult immuno-compromised mice and CD34+ 
cells were given 48 h later, there was improved neovascularization, increased migration of 
neural progenitor cells to the injured area and improved functional recovery [89]. In a neona-
tal HI model in postnatal day 12 mice, administration of CD34+ cells increased neurogenesis 
in the dentate gyrus 14 days later, but this effect was sex-specific and only seen in males 
[90]. Another study by Tsuji and colleagues [91] found that when CD34+ cells were given 
to postnatal day 12 mice following a middle cerebral artery occlusion, there was no change 
in cerebral blood flow, no difference in tissue loss at 9-day post-injury and no difference in 
behavioral outcomes, although at 7 weeks post-stroke, there was an improvement in tissue 
loss [91]. When comparing mononuclear cells, CD34+ cells or CD34− cells, all cell fractions 
reduced neurofunctional deficits and reduced lesion volume in a rodent stroke model, but 
UCB-derived mononuclear cells (with all cell types present), were more beneficial than the 
other cells fractions alone [92]. This study suggests that while CD34+ cells may play a role in 
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the neuroprotective benefits of UCB, there are other cells present in cord blood that may also 
contribute to protection against brain injury.
3.3. UCB-derived mesenchymal stromal cells
Mesenchymal stromal cells (MSCs) can be isolated from a number of sources including bone 
marrow, fat, umbilical cord tissue and dental pulp. MSCs have the ability to differentiate into 
mesodermal lineages to produce osteocytes, myocytes and adipocytes [93]. MSCs from UCB 
have been postulated to provide the principal neuroprotective benefit of UCB [94]. Initially, 
this proposal was based on the ability for MSCs to differentiate into a variety of cell types in 
response to cues from the microenvironment, including oligodendrocyte progenitor-like cells 
[2, 95]. More recent evidence suggests that the neuroprotective actions of MSCs are not due to 
engraftment or differentiation of MSCs within the brain. Rather, MSCs adapt and mediate the 
local response to HI via anti-inflammatory effects and secretion of growth and differentiation 
factors [96]. Using a neonatal stroke model in postnatal day 10 rats, UCB-MSCs were adminis-
tered intravenously within 6 h of the insult. After 28 days, there was decreased lesion volume, 
cell death, microglial activation, astrogliosis and functional improvement was observed in the 
rotarod and cylinder test [97]. Another study induced HI at postnatal day 7 and injected UCB-
MSCs directly to the brain 3 days after the HI injury, to show that labeled cells were detectable 
in the brain 7 days after administration and appeared to express glial fibrillary acidic protein 
(GFAP), an astrocyte marker. By day 28, there was reduced neuronal loss in the cortex and 
improved behavioral outcomes compared to controls [98].
Interestingly, however, it is now evident that MSCs are not present in all UCB samples. For 
example, one study reports as little as 10–30% success rate for isolation of MSCs from term 
UCB samples [99], and this percent is further reduced with cryopreservation [99]. Given the 
low frequency of MSCs in UCB, we postulate that other cell types are more likely to con-
tribute to the anti-inflammatory and neuroprotective effect observed with UCB treatment. 
Nevertheless, given the potent anti-inflammatory properties of MSCs, many studies have 
investigated the potential of UCB-derived MSCs for perinatal brain injury.
The current treatment for neonates that have suffered a severe HI injury at birth is hypo-
thermia, where the neonates are cooled to approximately 33–34°C within the first 6 h of life. 
Interestingly, a rodent study that examined severe neonatal HI brain injury, administered 
MSCs and hypothermia within 6 h of the HI insult and found that co-therapy was far more 
effective at reducing cell death, inflammation and behavioral deficits than either MSC or 
hypothermia treatment alone [100]. This finding is important, since hypothermia is now stan-
dard care for HIE in high resource countries and therefore any additional therapy would need 
to work synergistically with cooling.
3.4. UCB-derived endothelial progenitor cells
Endothelial progenitor cells (EPCs) were first identified in human peripheral blood [101]. 
EPCs are essential for vascular growth and homeostasis and play an integral role in  tissue 
repair and regeneration. While there remains much controversy over the classification 
of EPCs, in this review, we will discuss any cell from UCB that has endothelial potential, 
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 including CD133+ cells, endothelial colony-forming cells and late- and early-outgrowth endo-
thelial cells. It is well understood that EPCs are mobilized into the peripheral blood after trau-
matic, inflammatory or ischemic injuries and they can home to sites of injury and participate 
in neovascularization [102]. EPCs primarily work in two ways: (1) by physical incorporation 
into new blood vessels within the target tissue, therefore improving oxygenation and nutrient 
delivery into the injured area [103]; and (2) in a paracrine manner, by secreting factors that 
create a niche environment that can support differentiation of other progenitor cells [104, 105]. 
Umbilical cord blood (UCB) is a rich source of EPCs.
Studies have shown that circulating EPC levels are predictive of severe neurological impair-
ment after acute stroke, and increased EPC levels are correlated with good functional out-
come and reduced infarct size [106]. Despite recruitment of endogenous EPCs from bone 
marrow following injury cues, these mechanisms are easily overwhelmed and tissue regen-
eration fails. Systemic administration of expanded bone marrow-derived EPCs to adult mice 
after stroke results in significant protection against brain injury; reducing infarct volume, 
decreasing neutrophil infiltration, and increasing focal blood flow at 48 h after ischemia [106]. 
In a mouse model of focal ischemia, bone marrow-derived EPC administration induces blood 
vessel sprouting at the boundary of the ischemic lesion. This closely corresponded to elevated 
cerebral blood flow detected on perfusion-weighted MRI, indicating the presence of neovas-
cularization, while cells positive for markers of mature endothelial cells were incorporated 
into the vasculature [107]. UCB-derived EPCs accumulated in the stroke-affected hemisphere 
of rats, and acted to reduce stroke volume [108].
An in vitro study, using neural cells isolated from 3 day-old rats, cocultured the neural cells 
with EPCs in an hypoxic environment, and showed that the presence of EPCs increased 
cortico-spinal axonal growth by threefold, and decreased hypoxia-induced apoptosis [109], 
suggesting that EPCs play a direct role in neuroprotection. Ding and colleagues transfected 
EPCs with luciferin to enable live cell tracking after injection of the EPCs at 24-h post-stroke 
in adult mice and labelled EPCs were widely detected in the brain at 1 and 4 days after injec-
tion. At day 7, there was a faint signal, but the cells could not be detected at 14 days, despite 
a significant decrease in the infarct size, an increase in neural progenitor cells in the subven-
tricular zone and increased vascular density in the EPC-treated mice [110]. Recently, a study 
investigated the potential of EPCs for neonatal HI brain injury in severe combined immuno-
deficient (SCID) mice [111]. EPCs were administered 24-h post-HI-injury and, after 48 h, they 
had migrated towards the brain and motor function was improved.
3.5. UCB-derived T regulatory cells
T regulatory cells (Tregs) play an essential role in modulating the immune response, and infu-
sion of Tregs is beneficial for treatment of inflammatory disorders [112]. UCB is a rich source 
of highly naïve Tregs that demonstrate enhanced proliferation and functional potential com-
pared to Tregs isolated from adult blood [113]. To date, the main therapeutic use of Treg cells 
has been focused of preventing graft-versus-host-disease (GVHD). This research has been 
very promising and, as a result, groups have been developing cell expansion technologies 
as a way to increase cell yield and immunosuppressive function of Tregs isolated from UCB, 
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making them a more viable clinical and commercial therapy [114]. A recent clinical trial suc-
cessfully used expanded Tregs from UCB to prevent the incidence of GVHD following trans-
plantation of UCB [115]. The results from this trial were very promising with no reported 
adverse events and a reduced incidence of GVHD in the Treg-treated group.
Given the potent immunosuppressive ability of Tregs, they may play a very important role 
in suppressing neuroinflammation associated with hypoxia-ischemia, but, to date, no studies 
have examined the therapeutic potential of Tregs in neonatal brain injury. However, in an 
adult stroke model, intravenous Treg therapy significantly decreased cerebral inflammation, 
decreased brain infarct size and improved long-term neurological function [116]. Treg cells 
also reduced the neutrophil-mediated production of matrix metallopeptidase 9 (MMP9) and 
subsequently protected the integrity of the blood brain barrier [116]. A further study showed 
that administered Tregs were present in vivo for >12 days, they reduced expression of inflam-
matory cytokines in the plasma and improved immune function after stroke [117], where 
immuno-compromise is considered a very serious side effect following stroke.
3.6. UCB-derived monocyte derived suppressor cells
A recently discovered subset of immunosuppressive cells that are being keenly investigated 
are monocyte-derived suppressor cells (MDSCs)—a heterogeneous population of cells that 
include immature macrophages, granulocytes, dendritic cells and other myeloid cells [118, 119]. 
MDSCs are present in significantly higher number in UCB compared to adult peripheral 
blood, but cell number falls dramatically in the months after birth [3]. MDSCs can signifi-
cantly suppress T cell proliferation, T helper (Th)1, Th2 and Th17 cytokine production and 
activation of natural killer (NK) cells [120]. The mechanisms by which MDSCs elicit this effect 
is cell-contact dependent and also involves the secretion of soluble factors such as IFN-γ, 
iNOS and Arginase-1 [3, 121–123]. The therapeutic potential for MDSCs have been mostly 
investigated in relation to cancer, however emerging data suggests they may play a role in 
other inflammatory conditions. For example, in a multiple sclerosis mouse model, endog-
enous MDSCs were found in demyelinating lesions and their presence correlated with the 
time course of the disease. In vitro, these cells could significantly suppress T-cell responses, 
suggesting that indeed MDSCs may play a role in reducing neuroinflammation [123].
While the role of MDSCs have not been studied in neonatal brain injury, a recent study 
showed that depleting monocytes from UCB acted to decrease motor improvement and 
microglial suppression in an adult stroke animal model, suggesting that UCB-monocytes may 
actively mediate neuroprotective benefits of UCB [124]. Whether this function is directly due 
to MDSCs is yet to be elucidated, but these cells may be promising as a potential therapeutic 
target for suppressing inflammation in perinatal brain injury.
3.7. What is known about the mechanisms of how UCB cells protect against brain injury
Given the heterogeneity of cells with UCB, there are many potential mechanisms by which 
UCB could protect against perinatal brain injury, ranging from a receptor-mediated response to 
stimulation of factors released from the injured brain, to protecting against blood brain barrier 
and vascular damage, to anti-inflammatory potential through the secretion of specific cytokines.
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A potential mechanism by which UCB cells respond to and protect against brain injury is 
via stromal derived factor (SDF)-1. SDF-1 is upregulated in the neonatal brain 7-day post-HI 
injure and is derived from astrocytic end-feet processes along blood vessels and from endo-
thelial cells [125]. UCB mononuclear cells express the SDF-1 receptor, CXCR4 and inhibition 
of SDF-1 reduces migration of UCB cells to the lesion site following neonatal HI injury [126]. 
In addition, monocyte chemoattractant protein (MCP)-1 and macrophage inflammatory pro-
tein (MIP)-1 receptors are expressed on UCB cells and could be other potential receptors that 
allow migration of UCB cells to the injured brain [127].
Cytokines and chemokines play a central role in inflammation, and UCB cells have been 
shown to secrete MCP-1, interleukin (IL)-6, IL-8, IL-10, angiogenin, vascular endothelial 
growth factor, brain derived neurotrophic factor and platelet derived growth factor, which all 
have protective potential to mediate inflammation, apoptosis, cell survival and angiogenesis 
[128, 129]. Furthermore, coculture of UCB cells with neural cultures exposed to oxygen and 
glucose deprivation for over 3 days showed that UCB upregulated the expression of che-
mokines CCL5, CCL3 and CXCL10 and subsequently reduced neuronal apoptosis to levels 
observed in normoxic cultures [130].
Sonic hedgehog (Shh) has also been postulated to play an important role in the neuropro-
tective potential of UCB cells. It was shown that, following UCB administration, there was 
reduced neonatal brain injury in the cortex and this was accompanied by an increased expres-
sion of both Shh and Gli-1 [86]. Furthermore, when cyclopamine, an inhibitor of Shh, was 
administered prior to the UCB treatment, neuroprotection was abolished [86].
Another aspect that is frequently discussed in relation to cell therapies for brain injury is 
the necessity of cells to enter the brain to elicit an effect, and whether the blood brain barrier 
(BBB) needs to be disrupted for this to happen. A study in neonatal rats that received a HI 
injury used mannitol, a drug that can increase BBB permeability, followed by administration 
of UCB cells [131]. They found that expression of neurotrophic factors was increased in the 
animals that received both UCB cells and mannitol, compared to either therapy alone, and 
neurobehavioral outcomes were improved at 7- and 14-day post-HI. Interestingly, mannitol 
did not increase the rate of UBC engraftment within the brain, but clearly disrupting the BBB 
increased the effectiveness of UCB therapy. This could be important as it suggests that man-
nitol could extend the therapeutic window for UCB treatment after birth.
4. UCB in clinical trials
The first successful UCB transplantation was performed in 1988 in which the cells were able 
to reconstitute the immune system of a patient with Fanconi’s anemia [132]. Since then, over 
20,000 UCB transplants have been performed with more than 3000 UCB transplants now 
conducted each year [133]. UCB is routinely used in the clinic for acute leukemia, aplastic 
anemia, lymphomas, hemoglobinopathy and sickle cell disease [134–136]. Initially, there was 
concern that UCB therapies may struggle to translate to adult conditions as the number of 
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cells  present in UCB units is generally limited and less than required to treat adult conditions 
or when multiple doses are required. However, it is now been shown that it is feasible to use 
two independent UCB units at once to overcome insufficient cells present in a single UCB 
unit [137]. Furthermore, with rapid advances in technology for the expansion of stem cells, it 
is likely that expanded stem cells isolated from UCB units will allow administration of larger 
cell doses from a single UCB unit [133].
Cerebral palsy (CP) is the most well-recognized condition resulting from perinatal brain 
injury. It is a clinically described complex of motor symptoms, with disability ranging from 
mild motor coordination dysfunction through to significant hemiplegia or quadriplegia, 
reflecting variable injury to the young brain. The motor disabilities that define CP are also 
often coexistent with other serious deficits—1 in 2 children with CP have intellectual dis-
abilities including cognition, memory, learning and behavior deficits; 1 in 4 have epilepsy; 
1 in 4 cannot talk; 1 in 4 are incontinent [138]. Parents of infants with CP are actively seeking 
new treatment options, including the use of stem cell therapies, particularly UCB therapy 
[139]. Cerebral palsy is currently ranked as the second most commonly treated condition 
with stem cells, and Australia is the third highest ranked country of patient origin for over-
seas  treatments [140].
There are now a number of registered clinical trials, and a few completed trials, investigat-
ing UCB cell treatment for CP in children ranging from 10 months to 20 years old (Table 1). 
Two randomized control trials (RCT) have published results; Min and colleagues [139] inves-
tigated allogeneic UCB in combination with erythropoietin (EPO) vs. EPO and rehabilita-
tion or rehabilitation alone. Their cohort was treated between 10 months and 10 years of age 
after diagnosis of CP, and children received an average 30 million cells per kg. At 6 months 
after treatment, improvements in gross motor function measure and cognitive scores were 
observed using the Bayley Scale. Unfortunately, however, this trial did not assess the efficacy 
of UCB alone. The second RCT treated CP patients between 6- and 20-year old with allogeneic 
UCB and they received up to 20 million cells per kg [141]. At 1- and 3-month posttreatment, 
muscle strength improved and by 6 months improvements were observed on gross motor 
function measure. Interestingly, they noted that the higher the cell dose given to the patient 
the better the outcome, suggesting that cell dose is critical for efficacy. This is confirmed by a 
further study in which administration of greater number of allogeneic UCB cells was associ-
ated with better outcome at 36 months [142]. A handful of smaller, non-RCT trials have also 
added to our knowledge on the efficacy of UCB for treating established CP [142–144]. CP 
patients with diplegic or hemiplegic deficits improved more after receiving autologous UCB 
cells, than children with quadriplegic disorders [143]. A Duke University trial has been con-
ducted for administration of fresh autologous UCB to infants diagnosed with hypoxic isch-
emic encephalopathy and undergoing hypothermia treatment [144]. While this study has not 
yet reported neuroprotective efficacy, it is the first to show safety and feasibility for the early 
use of UCB cells as a prevention/early intervention therapy, rather than a reparative therapy 
for established CP. The same group at Duke University have a number of clinical trials reg-
istered (Table 1) investigating both autologous and sibling matched UCB transplantation, 
while reports are encouraging, we still await results from these trials.
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Study title Main objective Institution Treatment Current status Trial 
identifier
Allogenic umbilical 
cord blood and 
erythropoietin 
combination 
therapy for cerebral 
palsy
To determine efficacy of 
umbilical cord blood and 
erythropoietin combination 



















blood therapy for 
cerebral palsy
To evaluate the efficacy 
of umbilical cord blood 











study of autologous 
umbilical cord 
blood reinfusion 
in children with 
cerebral palsy
To determine the efficacy of 
a single intravenous infusion 
of autologous umbilical 
cord blood for the treatment 













for children with 
cerebral palsy
To evaluate the efficacy 
of umbilical cord blood 










Assessment of the 
safety of allogeneic 
umbilical cord 
blood infusions 
in children with 
cerebral palsy
A single site, phase I, 
prospective study of the 















blood therapy in 
children with CP
To analyze cytokines 
related to clinical outcomes 
of allogeneic umbilical cord 












banked cord blood 
or bone morrow 
stem cells in children 
with cerebral palsy 
(CP). (ACT for CP)
To compare the safety 
and effectiveness of two 
types of stem cells, (either 
banked cord blood or 
bone marrow), in children 















cord blood stem 
cell infusion for 
the treatment of 
cerebral palsy in 
children
To test the safety and 
effectiveness of a cord 
blood infusion in children 
who have motor disability 
due to cerebral palsy. The 
subjects will be children 
whose parents have saved 
their infant’s cord blood, 
who have non-progressive 
motor disability, and whose 
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Study title Main objective Institution Treatment Current status Trial 
identifier
Characterization of 
the cord blood stem 
cell in situation of 
neonatal asphyxia 
(NEOCORD)
To characterize cord blood 
stem cells of neonates with 
neonatal asphyxia and to 












cells in newborns 
with oxygen 
deprivation
To determine if the 
plasticity of autologous 
intravenous administration 
of cord blood stem cells 
would improve the clinical 













therapy with EPO 
in children with CP
A randomized controlled 
study aims to evaluate 
the efficacy and safety of 
allogeneic umbilical cord 
blood therapy combined 
with erythropoietin for 










blood infusion in 
cerebral palsy
To reveal the safety and 
feasibility of combination 
therapy with autologous 
cord blood mononuclear 
cells (CB) and G-CSF 
as well as repeated 
administration of 










therapy of cord 
blood and G-CSF 
for patients with 
brain injury or 
neurodegenerative 
disorders
To investigate the 
efficacy and safety of 
the combination therapy 
of allogeneic umbilical 
cord blood (UCB) and 
granulocyte-colony 
stimulating factor (G-CSF) 
for patients with brain 














To test feasibility of 
collection, preparation and 
infusion of autologous 
umbilical cord blood in the 
first 14 days after birth if 
the baby is born premature 









blood cells for 
brain injury in term 
newborns
To test feasibility and safety 
of collection, preparation 
and infusion of autologous 
umbilical cord blood during 
the first 3 days of age if the 
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A meta-analysis on the efficacy of all reported stem cell trials for children with CP was 
recently performed, demonstrating a statistically significant intervention effect when patients 
were followed short-term to 6 months following treatment [145]. Furthermore, the effect was 
greatest in the trials using UCB, and overall, the treatment effect highly favors the use of UCB 
with or without rehabilitation to treat children with CP (Figure 2).
The first autologous transplant of UCB for pediatric ischemic stroke has recently been reported 
[146]. The work reports a child with right spastic hemiplegia who received 250 million UCB 
mononuclear cells at 5 years of age. At 3 months after treatment, there was an improvement in 
motor control, and further improvements were observed at 18 months,  however, no change was 






A pilot study to test 
feasibility of collection, 
preparation and infusion 
of a baby’s own umbilical 
cord blood in the first 14 
days after birth if the baby 





















To compare the efficacy 
of cell therapy and 














Information obtained from ClinicalTrials.gov.
Table 1. Current clinical trials being conducted, or recently completed, using umbilical cord blood in regenerative 
medicine therapies for the management of cerebral palsy and ischemic brain injury in the newborn.
Figure 2. Forest plot showing the gross motor function changes from UCB transplantation for treatment of established 
cerebral palsy (adapted with permission from Novak et al. [145]).
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observed on MRI. Another recent trial investigated the use of UCB for congenital  hydrocephalus, 
where patients received multiple doses of autologous UCB with a median cell dose of 19 million 
cells/kg/infusion. No adverse events were reported while the UCB was also well-tolerated [147].
5. Future challenges for translation of umbilical cord blood therapies
Almost all available evidence supports that UCB cell therapy provides neuroprotective and/
or neuroregenerative benefits in response to perinatal brain injury and established cerebral 
palsy. There do, however, remain a number of important questions around the best practice 
treatment with UCB cells to provide optimized outcomes for infants with perinatal brain 
injury. These questions are principally centered around whether whole cord blood (mono-
nuclear cells) provides the best strategy, or whether individual cells (or combinations or cells) 
from cord blood should be expanded and subsequently administered to improve cell yield. 
Using this approach, cell therapy could be individualized depending on the pregnancy or 
birth complication. It is also not yet known what dose of cells is optimal, and when the cells 
should be administered relative to insult and diagnosis to provide the best outcome. All of 
these questions are best answered using animal models of chorioamnionitis, preterm birth, 
fetal growth restriction or birth asphyxia. A critical aim of designing novel therapies for peri-
natal brain injury is extending the treatment window so that cell therapy could be utilized for 
days to weeks after birth, not just within the 6 h of birth, as is necessary for hypothermia com-
mencement in newborns with hypoxic ischemic encephalopathy. Ideally, cell therapy must 
be effective at mediating a spectrum of adverse events that occur within the perinatal brain, 
such as reducing glial scar formation, inflammation and neuronal cell death. In this review, 
we reveal that many cells derived from UCB have the potential to suppress inflammation and 
reduce brain injury when they are administered within 3-day post-injury. These results are 
encouraging, but it is important to appreciate that a successful and effective cell therapy will 
combine anti-inflammatory and neuroprotective abilities that will allow the ultimate goal of 
novel therapies for cerebral palsy, permitting a longer therapeutic window.
6. Conclusions
Cerebral palsy is caused by injury to the developing brain, with the timing and severity of 
the insult underlying the heterogeneity of CP. Clinical trials are already underway to treat 
established CP with UCB mononuclear cells with some positive results, however. It is widely 
appreciated that treating brain injury as early as possible will demonstrate the most profound 
benefits. Given the good safety profile of UCB therapies, with the low incidence of transplant 
rejection, due to the increased number of immature progenitors cells and naïve immune cells, 
it is clear that UCB is a safe source of cells for transplantation. Preclinical data are accumulating 
exciting evidence for the mechanisms of neuroprotection by stem cells, and meta-analysis of 
clinical trials shows that UCB cells mediate significant improvement for children with CP. The 
immediate imperative is to optimize the benefits of UCB therapy by conducting  well-planned 
strategic animal studies followed by human clinical trials that can further inform the use of 
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targeted neuroprotective cell therapies for the prevention or repair of perinatal brain injury in 
order to provide long-term improvements for children after compromised pregnancy or birth.
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